Search

Your search keyword '"Bauman G."' showing total 597 results
Start Over Author "Bauman G."
597 results on '"Bauman G."'

1. Professional Development and School Counselors: A Study of Utah School Counselor Preferences and Practices

Author

Howell, Scott L., Bitner, Kathryn S., Henry, N. Jonnell, Eggett, Dennis L., Bauman, G. John, Sawyer, Octavia, and Bryant, Russell

Abstract

This study investigated the professional development needs, preferences, and practices of secondary school counselors in Utah. Participants included 226 secondary school counselors who responded to a 20-question survey instrument. The respondents revealed that most of them exceed minimum licensure requirements for professional development but also spend significant amounts of personal time and expense to do so. The counselors also identified obstacles with, and preferences toward, professional development that they experience in the increasingly complex and sophisticated school environment. Findings will inform professional development policy and practice in the state and also provide a basis for future research. (Contains 2 tables.)

Published
2007

2. Multimodal Biomarkers that Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance

Author

Berman, D. M., primary, Lee, A. Y., additional, Lesurf, R., additional, Patel, P. G., additional, Ebrahimizadeh, W., additional, Bayani, J., additional, Lee, L. A., additional, Boufaied, N., additional, Selvarajah, S., additional, Jamaspishvili, T., additional, Guérard, K.-P., additional, Dion, D., additional, Kawashima, A., additional, Clarke, G. M., additional, How, N., additional, Jackson, C. L., additional, Scarlata, E., additional, Siddiqui, K., additional, Okello, J. B. A., additional, Aprikian, A. G., additional, Moussa, M., additional, Finelli, A., additional, Chin, J., additional, Brimo, F., additional, Bauman, G., additional, Loblaw, A., additional, Venkateswaran, V., additional, Buttyan, R., additional, Chevalier, S., additional, Thomson, A., additional, Park, P. C., additional, Siemens, D. R., additional, Lapointe, J., additional, Boutros, P. C., additional, and Bartlett, J. M. S., additional

Published
2023
Full Text
View/download PDF

4. Registration of In Vivo Prostate Magnetic Resonance Images to Digital Histopathology Images

Author

Ward, A. D., Crukley, C., McKenzie, C., Montreuil, J., Gibson, E., Gomez, J. A., Moussa, M., Bauman, G., Fenster, A., Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Doug, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Madabhushi, Anant, editor, Dowling, Jason, editor, Yan, Pingkun, editor, Fenster, Aaron, editor, Abolmaesumi, Purang, editor, and Hata, Nobuhiko, editor

Published
2010
Full Text
View/download PDF

9. Effects of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis: a comprehensive assessment using spirometry, lung-clearance-index, functional and structural lung MRI

Author

Streibel, C, additional, Willers, C, additional, Pusterla, O, additional, Bauman, G, additional, Stranzinger, E, additional, Brabandt, B, additional, Bieri, O, additional, Bullo, M, additional, Korten, I, additional, Krüger, L, additional, Casaulta, C, additional, Latzin, P, additional, and Kieninger, E, additional

Published
2022
Full Text
View/download PDF

14. Effect of 18F-DCFPyL PET/CT (=PSMA PET) on the management of patients with suspected limited residual/recurrent disease following radical prostatectomy: Results of a prospective, multicenter registry trial

Author

Chin, J., primary, Metser, U., additional, Zukotynski, K., additional, Mak, V., additional, Langer, D., additional, Maccrostie, P., additional, Finelli, A., additional, Kapoor, A., additional, Lavallee, L., additional, Klotz, L., additional, Hagerty, M., additional, Hildebrand, C., additional, and Bauman, G., additional

Published
2022
Full Text
View/download PDF

29. P034 MRI as the new gold standard in the assessment of cystic fibrosis lung disease severity? A bespoke cystic fibrosis-MRI protocol combining quantitative ventilation and structural MRI measures to replace CT

Author

Semple, T., primary, Edmondson, C., additional, Rawal, B., additional, Barnett, J., additional, Short, C., additional, Bauman, G., additional, Pusterla, O., additional, Bieri, O., additional, Tibiletti, M., additional, Parker, G.J.M., additional, Carr, S., additional, Hogg, C., additional, Davies, J.C., additional, and Padley, S., additional

Published
2019
Full Text
View/download PDF

30. WS17-4 The addition of sinus imaging to a quantitative cystic fibrosis lung MRI protocol demonstrates an association between sinus signal characteristics and lung disease severity

Author

Semple, T., primary, Edmondson, C., additional, Rawal, B., additional, Barnett, J., additional, Short, C., additional, Bauman, G., additional, Pusterla, O., additional, Bieri, O., additional, Tibiletti, M., additional, Parker, G.J.M., additional, Carr, S., additional, Hogg, C., additional, Davies, J.C., additional, and Padley, S., additional

Published
2019
Full Text
View/download PDF

32. Étude prospective multicentrique comparant l’IRM multiparamétrique (IRM-mp), la 18f-fluorocholine (fch) et la 68ga-psma tep/tdm chez des patients candidats à la radiothérapie de rattrapage après prostatectomie radicale et avec imagerie conventionnelle normale

Author

Pouliot, F., primary, Metser, U., additional, Bauman, G., additional, Weickhardt, A., additional, Davis, I., additional, Davies, R., additional, Punwani, S., additional, Chua, S., additional, Scott, A., additional, and Emmet, L., additional

Published
2018
Full Text
View/download PDF

33. Stereotactic ablative radiotherapy for oligometastatic cancers: Efficacy and toxicity results from the randomized SABR-COMET Trial

Author

Senan, S., primary, Olson, R., additional, Harrow, S., additional, Gaede, S., additional, Louie, A., additional, Haasbeek, C., additional, Mulroy, L., additional, Lock, M., additional, Rodrigues, G., additional, Yaremko, B., additional, Schellenberg, D., additional, Ahmad, B., additional, Griffioen, G., additional, Senthi, S., additional, Liu, M., additional, Moore, K., additional, Currie, S., additional, Bauman, G., additional, Warner, A., additional, and Palma, D., additional

Published
2018
Full Text
View/download PDF

35. Prospective, multinational comparison of magnetic resonance imaging (mp-MRI and WB–MRI) F-18 fluorocholine (FCH) and Ga-68 PSMA in high risk men being considered for salvage radiation treatment for biochemical failure post radical prostatectomy

Author

Emmett, L., primary, Metzer, U., additional, Bauman, G., additional, Pouliot, F., additional, Hicks, R., additional, Chua, S., additional, Davis, I., additional, Punwani, S., additional, Weikhardt, A., additional, and Scott, A., additional

Published
2018
Full Text
View/download PDF

36. Erratum to: Survival prediction in high-grade gliomas using CT perfusion imaging [J Neurooncol (2015) 123, 93-102, DOI 10.1007/s11060-015-1766-5]

Author

Yeung T. P. C., Wang Y., He W., Urbini B., Gafa R., Ulazzi L., Yartsev S., Bauman G., Lee T. -Y., Fainardi E., Baruzzi A., Albani F., Calbucci F., D'alessandro R., Michelucci R., Brandes A., Eusebi V., Ceruti S., Tamarozzi R., Emiliani E., Cavallo M., Franceschi E., Tosoni A., Fiorica F., Valentini A., Depenni R., Mucciarini C., Crisi G., Sasso E., Biasini C., Cavanna L., Guidetti D., Marcello N., Pisanello A., Cremonini A. M., Guiducci G., de Pasqua S., Testoni S., Agati R., Ambrosetto G., Bacci A., Baldin E., Baldrati A., Barbieri E., Bartolini S., Bellavista E., Bisulli F., Bonora E., Bunkheila F., Carelli V., Crisci M., Dall'occa P., de Biase D., Ferro S., Franceschi C., Frezza G., Grasso V., Leonardi M., Marucci G., Morandi L., Mostacci B., Palandri G., Pasini E., Pastore Trossello M., Pession A., Poggi R., Riguzzi P., Rinaldi R., Rizzi S., Romeo G., Spagnolli F., Tinuper P., Trocino C., Dall'agata M., Frattarelli M., Gentili G., Giovannini A., Iorio P., Pasquini U., Galletti G., Guidi C., Neri W., Patuelli A., Strumia S., Faedi M., Casmiro M., Gamboni A., Rasi F., Cruciani G., Cenni P., Dazzi C., Guidi A. R., Zumaglini F., Amadori A., Pasini G., Pasquinelli M., Pasquini E., Polselli A., Ravasio A., Viti B., Sintini M., Ariatti A., Bertolini F., Bigliardi G., Carpeggiani P., Cavalleri F., Meletti S., Nichelli P., Pettorelli E., Pinna G., Zunarelli E., Artioli F., Bernardini I., Costa M., Greco G., Guerzoni R., Stucchi C., Iaccarino C., Ragazzi M., Rizzi R., Zuccoli G., Api P., Cartei F., Colella M., Fallica E., Farneti M., Frassoldati A., Granieri E., Latini F., Monetti C., Saletti A., Schivalocchi R., Sarubbo S., Seraceni S., Tola M. R., Zini G., Giorgi C., Montanari E., Cerasti D., Crafa P., Dascola I., Florindo I., Giombelli E., Mazza S., Ramponi V., Servadei F., Silini E. M., Torelli P., Immovilli P., Morelli N., Vanzo C., Nobile C., Yeung T.P.C., Wang Y., He W., Urbini B., Gafa R., Ulazzi L., Yartsev S., Bauman G., Lee T.-Y., Fainardi E., Baruzzi A., Albani F., Calbucci F., D'alessandro R., Michelucci R., Brandes A., Eusebi V., Ceruti S., Tamarozzi R., Emiliani E., Cavallo M., Franceschi E., Tosoni A., Fiorica F., Valentini A., Depenni R., Mucciarini C., Crisi G., Sasso E., Biasini C., Cavanna L., Guidetti D., Marcello N., Pisanello A., Cremonini A.M., Guiducci G., de Pasqua S., Testoni S., Agati R., Ambrosetto G., Bacci A., Baldin E., Baldrati A., Barbieri E., Bartolini S., Bellavista E., Bisulli F., Bonora E., Bunkheila F., Carelli V., Crisci M., Dall'occa P., de Biase D., Ferro S., Franceschi C., Frezza G., Grasso V., Leonardi M., Marucci G., Morandi L., Mostacci B., Palandri G., Pasini E., Pastore Trossello M., Pession A., Poggi R., Riguzzi P., Rinaldi R., Rizzi S., Romeo G., Spagnolli F., Tinuper P., Trocino C., Dall'agata M., Frattarelli M., Gentili G., Giovannini A., Iorio P., Pasquini U., Galletti G., Guidi C., Neri W., Patuelli A., Strumia S., Faedi M., Casmiro M., Gamboni A., Rasi F., Cruciani G., Cenni P., Dazzi C., Guidi A.R., Zumaglini F., Amadori A., Pasini G., Pasquinelli M., Pasquini E., Polselli A., Ravasio A., Viti B., Sintini M., Ariatti A., Bertolini F., Bigliardi G., Carpeggiani P., Cavalleri F., Meletti S., Nichelli P., Pettorelli E., Pinna G., Zunarelli E., Artioli F., Bernardini I., Costa M., Greco G., Guerzoni R., Stucchi C., Iaccarino C., Ragazzi M., Rizzi R., Zuccoli G., Api P., Cartei F., Colella M., Fallica E., Farneti M., Frassoldati A., Granieri E., Latini F., Monetti C., Saletti A., Schivalocchi R., Sarubbo S., Seraceni S., Tola M.R., Zini G., Giorgi C., Montanari E., Cerasti D., Crafa P., Dascola I., Florindo I., Giombelli E., Mazza S., Ramponi V., Servadei F., Silini E.M., Torelli P., Immovilli P., Morelli N., Vanzo C., and Nobile C.

Subjects
PERNO, Gender, Glioblastoma, MGMT, Methylation
Abstract

Background: Clinical and molecular factors are essential to define the prognosis in patients with glioblastoma (GBM). O6-methylguanine-DNA methyltransferase (MGMT) methylation status, age, Karnofsky Performance Status (KPS), and extent of surgical resection are the most relevant prognostic factors. Our investigation of the role of gender in predicting prognosis shows a slight survival advantage for female patients. Methods: We performed a prospective evaluation of the Project of Emilia Romagna on Neuro-Oncology (PERNO) registry to identify prognostic factors in patients with GBM who received standard treatment. Results: A total of 169 patients (99 males [58.6%] and 70 females [41.4%]) were evaluated prospectively. MGMT methylation was evaluable in 140 patients. Among the male patients, 36 were MGMT methylated (25.7%) and 47 were unmethylated (33.6%); among the female patients, 32 were methylated (22.9%) and 25 were unmethylated (17.9%). Survival was longer in the methylated females compared with the methylated males (P = 0.028) but was not significantly different between the unmethylated females and the unmethylated males (P = 0.395). In multivariate analysis, gender and MGMT methylation status considered together (methylated females vs. methylated males; hazard ratio [HR], 0.459; 95% confidence interval [CI], 0.242-0.827; P = 0.017), age (HR, 1.025; 95% CI, 1.002-1.049; P = 0.032), and KPS (HR, 0.965; 95% CI, 0.948-0.982; P < 0.001) were significantly correlated with survival. Conclusions: Survival was consistently longer among MGMT methylated females compared with males. Gender can be considered as a further prognostic factor.

Published
2015

37. Ontario health technology assessment series: Prolaris cell cycle progression test for localized prostate cancer: A health technology assessment

Author

Bauman, G., Breau, R. H., Suzanne Kamel-Reid, Louie, A. V., and Pautlere, S.

Subjects
skin and connective tissue diseases
Abstract

Background Prostate cancer is very common and many localized tumours are non-aggressive. Determining which cancers are aggressive is important for choosing the most appropriate treatment (e.g., surgery, radiation, active surveillance). Current clinical risk stratification is reliable in forecasting the prognosis of groups of men with similar clinical and pathologic characteristics, but there is residual uncertainty at the individual level. The Prolaris cell cycle progression (CCP) test, a genomic test that estimates how fast tumour cells are proliferating, could potentially be used to improve the accuracy of individual risk assessment. This health technology assessment sought to determine the clinical utility, economic impact, and patients’ perceptions of the value of the CCP test in low-and intermediate-risk localized prostate cancer. Methods We conducted a systematic review of the clinical and economic evidence of the CCP test in low-and intermediate-risk, localized prostate cancer. Medical and health economic databases were searched from 2010 to June or July 2016. The critical appraisal of the clinical evidence included risk of bias and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group criteria. We also analyzed the potential budget impact of adding the CCP test into current practice, from the perspective the Ontario Ministry of Health and Long-Term Care. Finally, we conducted qualitative interviews with men with prostate cancer, on the factors that influenced their treatment decision-making. Results For the review of clinical effectiveness, we screened 3,021 citations, and two before-after studies met our inclusion criteria. In one study, the results of the CCP test appeared to change the treatment plan (from initial to final plan) in 64.9% of cases overall (GRADE rating of the quality of evidence: Very low). In the other study, the CCP test changed the treatment received in nearly half of cases overall, compared with the initial plan (GRADE: Very low). No evidence was available on clinical outcomes of patients whose treatment was informed by CCP results. For the review of cost-effectiveness, 100 citations were identified and screened. No studies met the inclusion criteria. In our economic evaluation, we estimated that publicly funding the CCP test would result in a total net budget impact of $41.3 million in the first 5 years, mostly due to the cost of the CCP test. In our model, the relatively small cost savings ($7.3 million) due to treatment change (increased use of active surveillance and decreased use of interventional treatment) was not large enough to offset the high cost of the test. Patients viewed the test as potentially helpful but, due to the complexity of treatment decision-making, were unsure the test would ultimately change their treatment choices. Conclusions We found no evidence to demonstrate the impact of the Prolaris CCP test on patient-important clinical outcomes. The limited evidence available shows that the test appears to provide information that, when considered in addition to clinical risk stratification, may change the treatment plan or actual treatment for some low-and intermediate-risk prostate cancer patients. As a result, there is insufficient data to inform the cost-effectiveness of the CCP test. Publicly funding the CCP test would result in a large incremental cost to the provincial budget.

Published
2017

43. PS1 -125 Assessment of Function and Quality of Life in a Phase II Multi-Institutional Clinical Trial of Fractionated Simultaneous In-Field Boost Radiotherapy for Patients with 1-2 Brain Metastases

Author

Bauman, G, primary, Yartsev, S, additional, Roberge, D, additional, MacRae, R., additional, Roa, W, additional, Panet-Raymond, V, additional, Masucci, L, additional, Yaremko, B, additional, D’Souza, D., additional, Palma, D., additional, Sexton, T., additional, Yu, E., additional, Pantarotto, J.R., additional, Ahmad, B., additional, Fisher, B., additional, Dar, A.R., additional, Lambert, C., additional, Pond, G., additional, Stitt, L., additional, Tay, K.Y., additional, and Rodrigues, G., additional

Published
2016
Full Text
View/download PDF

45. Erratum to: Survival prediction in high-grade gliomas using CT perfusion imaging

Author

Yeung, Tp, Wang, Y, He, W, Urbini, B, Gafà, R, Ulazzi, L, Yartsev, S, Bauman, G, Lee TY, Fainardi, E, Project of Emilia-Romagna Region on Neuro-Oncology (PERNO) Study Group Participants :Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., (Bologna), Trocino C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., (Forlı`-Cesena), Strumia S., Faedi, M., (IRCCS Istituto Scientifico Romagnolo per lo Studio, e la Cura dei Tumori), Casmiro, M., Gamboni, A., Rasi, F. (Faenza R. A. )., (Lugo, Cruciani G., RA), Cenni, P., Dazzi, C., Guidi, A. R., (Ravenna), Zumaglini F., Amadori, A., Pasini, G., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., (Rimini), Viti B., (Cattolica, Sintini M., RN), Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., (Modena), Zunarelli E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C. (Carpi M. O. )., Iaccarino, C, Ragazzi, M., Rizzi, R., (Istituto di Ricovero e Cura a Carattere Scientifico, Zuccoli G., Reggio, Emilia), Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M. R., Urbini, B., (Ferrara), Zini G., Giorgi, C., Montanari, E. (Fidenza P. R. )., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, Em., (Parma), Torelli P., Immovilli, P., Morelli, N., (Piacenza), Vanzo C., and Nobile, C. (Padova).

Subjects
Cancer Research, medicine.medical_specialty, Neuroradiology unit, Neurology, Oncology, business.industry, General surgery, Medicine, Neurology (clinical), business
Abstract

Baruzzi A. (Chair), Albani F., Calbucci F., D’Alessandro R., Michelucci R. (IRCCS Institute of Neurological Sciences, Bologna, Italy), Brandes A. (Department of Medical Oncology, Bellaria-Maggiore Hospitals, Bologna, Italy), Eusebi V. (Department of Hematology and Oncological Sciences ‘‘L. & A. Seragnoli’’, Section of Anatomic Pathology at Bellaria Hospital, Bologna, Italy), Ceruti S., Fainardi E., Tamarozzi R. (Neuroradiology Unit, Department of Neurosciences and Rehabilitation, S. Anna Hospital, Ferrara, Italy), Emiliani E. (Istituto Oncologico Romagnolo, Department of Medical Oncology, Santa Maria delle Croci Hospital, Ravenna, Italy), Cavallo M. (Division of Neurosurgery, Department of Neurosciences and Rehabilitation, S. Anna Hospital, Ferrara, Italy).

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results